PCT to Become the Manufacturing and Development Service Platform of Hitachi Chemical Advanced Therapeutics Solutions, LLC
Robert A. Preti, PhD, Chief Strategy Officer, Hitachi Chemical Life Sciences | September 21, 2017
The “PCT” you have come to recognize as a leading cell therapy industry CDMO over the past two decades will be, effective September 29, 2017, the brand name of the manufacturing and development service platform of Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS).
HCATS will offer globally harmonized manufacturing development and cell therapy manufacturing services. To broaden our offering based on the needs of our customers, HCATS may come to offer other product lines in the future.
As always, our clients, remain our primary focus!
We are now actively expanding in capacity, geographic footprint, and services to better serve our clients, including:
Asian Operations: Opening our Yokohama CDMO facility in April of 2018
European Operations: The global platform is expected to expand to include Europe
U.S. Commercial Manufacturing: Investing tens of millions of dollars to bring commercial manufacturing services online
The change of our company name, logo, and positioning of PCT represents our commitment to leverage the resources of our parent company Hitachi Chemical Co. to develop a global superior delivery platform.
While my role has expanded to manage the Regenerative Medicine Business Sector within Hitachi Chemical Co., I will remain CEO and President of HCATS, which includes leadership of the PCT service platform.
We look forward to increasing the value we deliver to existing and future clients by providing high-quality, scalable, innovative, reliable and cost-efficient manufacturing platforms and services to advance the commercialization of cellular therapies.
You may have questions and we look forward to hearing from you. Please feel free to reach out to us through your account manager at your convenience.
Thank you for your business and for the trust you have placed in us. There are great things in store for HCATS and in our ability to serve you through the PCT service platform.
Robert A. Preti, PhD, Chief Strategy Officer, Hitachi Chemical Life SciencesRobert “Bob” Preti is the co-founder of Hitachi Chemical Advanced Therapeutics Solutions ("HCATS", formerly PCT) and the visionary behind its successful growth and development strategy over its first two decades.
Subscribe to our blog for instant updates on challenges and trends in cell therapy development, manufacturing and commercialization.